Personalis’ (PSNL) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Personalis (NASDAQ:PSNLFree Report) in a research note published on Friday, Benzinga reports. They currently have a $3.50 price target on the stock.

Separately, Lake Street Capital started coverage on shares of Personalis in a research report on Tuesday, April 30th. They issued a buy rating and a $4.00 price objective for the company.

View Our Latest Analysis on PSNL

Personalis Price Performance

Personalis stock opened at $1.22 on Friday. The stock has a market cap of $63.37 million, a price-to-earnings ratio of -0.64 and a beta of 1.87. Personalis has a 1 year low of $0.89 and a 1 year high of $2.43. The firm has a 50-day moving average of $1.38 and a two-hundred day moving average of $1.49.

Personalis (NASDAQ:PSNLGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.18. The company had revenue of $19.53 million during the quarter, compared to analysts’ expectations of $18.49 million. Personalis had a negative net margin of 124.89% and a negative return on equity of 58.31%. Research analysts expect that Personalis will post -1.26 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

Several large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio bought a new position in shares of Personalis during the 1st quarter worth approximately $29,000. Virtu Financial LLC bought a new position in shares of Personalis during the 1st quarter worth approximately $41,000. Pathstone Family Office LLC raised its stake in shares of Personalis by 149.3% during the 3rd quarter. Pathstone Family Office LLC now owns 37,081 shares of the company’s stock worth $45,000 after acquiring an additional 22,204 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of Personalis during the 4th quarter worth approximately $152,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Personalis by 58.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock worth $142,000 after acquiring an additional 34,900 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

(Get Free Report)

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

Read More

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.